Home    About NDEI    Supporters   Site Map   FAQ   Contact Us   
 
      
Home
Slide Library
Clinical Literature
On-Demand Programs
Treatment Guidelines
Patient Education
Clinical Trials
Product Indications
Calendar Of Events
Glossary
Other Resources















Online HCP community for clinically relevant information and skillfully designed programs that address practice gaps in diabetes
Welcome to NDEI.org, the website of the National Diabetes Education Initiative.           Register
May 17, 2012
What's New
Clinical Insights in Diabetes

 


CI New Issue

 
Reports of the latest diabetes research. Now available: Expert commentary from NDEI.org Education Council Member Vivian Fonseca, MD, on the DURATION-4 trial. 

 

 

Diabetes Clinical Guidelines and Recommendations

Treatment Guidelines

 
ADA 2012 Clinical Practice Recommendations are here!
 
Slide Library

Slide Library

 

March Madness may be over but we’re still celebrating! 

For a limited time, you can download all of our March Madness slides. Click the “March Madness” folder in our Slide Library for new data on DURATION-4, ACCORD, STAMPEDE, and more.  

Patient Management Tools

Patient Management Tools

 
Handouts on a number of topics that supplement patient management.

Also available: Patient Adherence Tracking Tool that can be kept in the patient's chart and used during every visit to reinforce key treatment and management messages.


 
Is your information current?

 


Current Info Whats New

 

Don’t miss important updates from NDEI.org! Login and click "Edit Profile" to make sure we have your current information. 

 

 




FDA Alerts
  Information for Healthcare Professionals: Reminder to enroll in the Avandia-Rosiglitazone Medicines Access Program 
 

Update 11/4/11: Update 11/4/11: The FDA is reminding healthcare providers and patients about the need to enroll in the Avandia-Rosiglitazone Medicines Access Program by November 17, 2011 to continue prescribing and receiving rosiglitazone-containing medicines (Avandia, Avandamet, Avandaryl). After November 18, 2011, rosiglitazone medicines will no longer be available through retail pharmacies and will only be available by mail order through specially certified pharmacies participating in the program. 

Click here for additional information. 

  Information for Healthcare Professionals: Potential Risks Associated With Rosiglitazone (Marketed as Avandia®) 
 

Update 2/3/11: Avandia labels now contain updated information about cardiovascular risks and use in certain patients.

The FDA announced that information on the cardiovascular risks (including heart attack) of the diabetes drug, rosiglitazone, has been added to the physician labelig and patient Medication Guide. This information was first announced by FDA on September 23, 2010 as part of new restrictions for prescribing and use of this drug.

In addition to describing the cardiovascular risks, the drug labels have been revised to state that rosiglitazone and rosiglitazone-containing medicines should only be used:
 

  • In patients already being treated with these medicines 
  • In patients whose blood sugar cannot be controlled with other antidiabetic medicines and who, after consulting with their healthcare professional, do not wish to use pioglitazone-containing medicines (Actos, Actoplus Met, Actoplus Met XR, or Duetact) 

Click here for additional information. 

  Information for Healthcare Professionals: New Restrictions to the Prescribing and Use of Rosiglitazone (Marketed as Avandia®, Avandamet, and Avandaryl) 
 

Update 5/18/11: FDA announced new restrictions to the prescribing and use of rosiglitazone-containing medicines (Avandia, Avandamet™, and Avandaryl™). Healthcare providers and patients must enroll in a special program to prescribe and receive these drugs.

FDA has modified the REMS for Avandamet and Avandaryl because previously, the REMS consisted of only a Medication Guide. The REMS, which now includes a restricted access and distribution program, applies to all three rosiglitazone products. 

Click here for additional information. 

 Click here for the Avandia-Rosiglitazone Medicines Access Program. 

  Information for Healthcare Professionals: Post-Marketing Reports of Altered Kidney Function Associated with Exenatide (Marketed as Byetta™) 
 

Update 11/2/09: FDA has approved revisions to the drug label for Byetta (exenatide) to include information on post-marketing reports of altered kidney function, including acute renal failure and insufficiency. 

Changes include: 

  • Information regarding post-market reports of acute renal failure and insufficiency, highlighting that Byetta should not be used in patients with severe renal impairment (creatinine clearance <30 ml/min) or end-stage renal disease 
  • Recommendations to healthcare professionals that caution should be applied when initiating or increasing doses of Byetta from 5 mcg to 10 mcg in patients with moderate renal impairment (30 to 50 ml/min) 
  • Recommendations that healthcare professionals monitor carefully for the development of kidney dysfunction, and evaluate the continued need for Byetta if kidney function is suspected while using the product 
  • Information about kidney dysfunction in the patient Medication Guide to help patients understand the benefits and potential risks associated with Byetta 

Click here for additional information. 




  

Quick Links to the Most Timely Content on the Internet

The links below search the National Library of Medicine's Medline database (PubMed) for abstracts posted during the previous 7 calendar days.  The links are updated daily to reflect the addition of new content.

Please contact us through info@ndei.org with suggestions for additional search terms.

Search for new abstracts posted within the past:

Insulin Resistance Patient Management Alpha-Glucosidase Inhibitors
Metabolic Syndrome Novel Therapies Diabetes and Statins
Diabetes and Cardiovascular Disease Thiazolidinediones Diabetes and ACE Inhibitors
Beta-cell Function Biguanides Diabetes and Dyslipidemia
Glycemic Control Sulfonylureas Epidemiology of Diabetes








Advertisement
 

Sponsored by KnowledgePoint360 Group, LLC, Lyndhurst, NJ.
Copyright © 2012 KnowledgePoint360 Group, LLC. All rights reserved.
National Diabetes Education Initiative and
KnowledgePoint360 are trademarks of KnowledgePoint360 Group, LLC.
 
Editorial Policy - Advertising Policy - Disclaimer Statement - Privacy Statement